Income Taxes (Details 2) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Tax Carryforwards
Federal statutory income tax rate (percent)									35.00%	35.00%	35.00%
Reconciliation of Income Tax Expense:
(Loss) income from continuing operations before provision for (benefit from) income taxes	$ (178,594,000)	$ (166,577,000)	$ (158,396,000)	$ (231,308,000)	$ (19,568,000)	$ (118,900,000)	$ (53,793,000)	$ (433,783,000)	$ (734,875,000)	$ (626,044,000)	$ 31,996,000
Expected tax provision (benefit)									(257,206,000)	(219,115,000)	11,199,000
State taxes, net of federal benefit									1,124,000	3,844,000	1,693,000
Foreign rate differential									39,335,000	79,799,000	46,168,000
Tax credits									(33,788,000)	(16,775,000)	(1,791,000)
Unbenefitted operating losses									241,037,000	(29,900,000)	(63,189,000)
Non-deductible expenses									18,756,000	9,614,000	3,084,000
Rate change									(1,826,000)	50,076,000	3,275,000
Other									(474,000)	35,000	(714,000)
Provision for (benefit from) income taxes	2,043,000	3,419,000	693,000	803,000	1,352,000	2,555,000	558,000	(126,887,000)	6,958,000	(122,422,000)	(275,000)
Deferred tax assets:
Net operating loss	996,172,000				850,946,000				996,172,000	850,946,000
Tax credit carryforwards	265,339,000				180,380,000				265,339,000	180,380,000
Intangible assets	3,174,000				26,105,000				3,174,000	26,105,000
Deferred revenues	15,771,000				25,158,000				15,771,000	25,158,000
Stock-based compensation	61,527,000				63,521,000				61,527,000	63,521,000
Inventories	13,395,000				26,278,000				13,395,000	26,278,000
Accrued expenses	37,699,000				52,470,000				37,699,000	52,470,000
Currency translation adjustment	0				217,000				0	217,000
Construction financing lease obligation	175,853,000				152,688,000				175,853,000	152,688,000
Gross deferred tax assets	1,568,930,000				1,377,763,000				1,568,930,000	1,377,763,000
Valuation allowance	(1,409,936,000)				(1,243,664,000)				(1,409,936,000)	(1,243,664,000)
Total deferred tax assets	158,994,000				134,099,000				158,994,000	134,099,000
Deferred tax liabilities:
Property and equipment	(158,994,000)				(134,099,000)				(158,994,000)	(134,099,000)
Acquired intangibles	(11,544,000)				0				(11,544,000)	0
Net deferred tax liabilities	(11,544,000)				0				(11,544,000)	0
Deferred tax assets recognized in prepaid expenses and other current assets	3,500,000				0				3,500,000	0
Deferred tax liabilities recognized in other liabilities, excluding current portion	15,044,000				0				15,044,000	0
Reconciliation of unrecognized tax benefits
Unrecognized tax benefits beginning of year				2,024,000				4,106,000	2,024,000	4,106,000
Gross change for current year positions									0	1,325,000
Decrease for prior period positions									(27,000)	(290,000)
Decrease due to settlements and payments									(1,117,000)	0
Decrease due to statute limitations									0	(185,000)
Deconsolidation of Alios									0	(2,932,000)
Unrecognized tax benefits end of year	880,000				2,024,000				880,000	2,024,000	4,106,000
Decreased in valuation allowance									(166,300,000)
Estimated reduction in unrecognized tax benefits in next fiscal year	500,000								500,000
Federal
Deferred tax liabilities:
Operating loss carryforwards	3,600,000,000								3,600,000,000
Tax credit carryforwards	172,400,000								172,400,000
Operating loss carryforwards that will increase APIC when used to reduce income taxes payable	908,500,000								908,500,000
State
Deferred tax liabilities:
Operating loss carryforwards	750,800,000								750,800,000
Tax credit carryforwards	95,900,000								95,900,000
Reconciliation of unrecognized tax benefits
Unrecognized tax benefits end of year	98,400,000								98,400,000
BioAxone Biosciences, Inc
Deferred tax liabilities:
Deferred tax liabilities recognized in other liabilities, excluding current portion	$ 11,500,000								$ 11,500,000